| Date | Time | Source | Headline | Symbol | Company |
| 02/14/2020 | 5:35PM | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:ARQL | ArQule Inc |
| 02/14/2020 | 12:20PM | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:ARQL | ArQule Inc |
| 02/12/2020 | 5:03PM | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:ARQL | ArQule Inc |
| 02/12/2020 | 12:05PM | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:ARQL | ArQule Inc |
| 02/10/2020 | 1:43PM | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:ARQL | ArQule Inc |
| 02/05/2020 | 11:29AM | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:ARQL | ArQule Inc |
| 01/27/2020 | 1:55PM | Edgar (US Regulatory) | Termination of Registration of a Class of Security Under Section 12(g) (15-12g) | NASDAQ:ARQL | ArQule Inc |
| 01/21/2020 | 6:00AM | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:ARQL | ArQule Inc |
| 01/21/2020 | 6:00AM | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:ARQL | ArQule Inc |
| 01/21/2020 | 6:00AM | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:ARQL | ArQule Inc |
| 01/06/2020 | 11:07AM | PR Newswire (US) | Moore Kuehn, PLLC Encourages Investors of KEM, ARQL, THOR, and LOGM to Contact the Firm | NASDAQ:ARQL | ArQule Inc |
| 12/12/2019 | 3:49PM | PR Newswire (US) | SHAREHOLDER ALERT: WeissLaw LLP Investigates ArQule, Inc. | NASDAQ:ARQL | ArQule Inc |
| 12/10/2019 | 3:02AM | Dow Jones News | Merck, Sanofi Push To Add Cancer Drugs -- WSJ | NASDAQ:ARQL | ArQule Inc |
| 12/09/2019 | 7:16PM | Dow Jones News | Big Drugmakers Push Deeper Into Cancer Treatment -- 4th Update | NASDAQ:ARQL | ArQule Inc |
| 12/09/2019 | 4:37PM | Dow Jones News | Big Drugmakers Push Deeper Into Cancer Treatment -- 3rd Update | NASDAQ:ARQL | ArQule Inc |
| 12/09/2019 | 3:12PM | Dow Jones News | U.S. Stocks Slip as Trade War Weighs on Chinese Exports | NASDAQ:ARQL | ArQule Inc |
| 12/09/2019 | 2:33PM | Dow Jones News | Big Drugmakers Push Deeper Into Cancer Treatment -- 2nd Update | NASDAQ:ARQL | ArQule Inc |
| 12/09/2019 | 11:13AM | Dow Jones News | Merck to Buy ArQule for $2.7 Billion -- Update | NASDAQ:ARQL | ArQule Inc |
| 12/09/2019 | 8:05AM | Business Wire | ArQule Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology... | NASDAQ:ARQL | ArQule Inc |
| 12/09/2019 | 7:37AM | PR Newswire (US) | (ARQL) Alert: Johnson Fistel Investigates Proposed Sale of ArQule, Inc.; Is $20 a Fair Price? | NASDAQ:ARQL | ArQule Inc |
| 12/09/2019 | 7:26AM | Dow Jones News | Merck to Buy ArQule for $2.7 Billion, or $20/Share | NASDAQ:ARQL | ArQule Inc |
| 12/09/2019 | 6:45AM | Business Wire | Merck to Acquire ArQule, Advancing Leadership in Oncology | NASDAQ:ARQL | ArQule Inc |
| 11/25/2019 | 7:00AM | Business Wire | ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual ... | NASDAQ:ARQL | ArQule Inc |
| 11/13/2019 | 7:00AM | Business Wire | ArQule to Participate in the Jefferies London Healthcare Conference on November 20, 2019 | NASDAQ:ARQL | ArQule Inc |
| 11/06/2019 | 9:05AM | Business Wire | ArQule Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversi... | NASDAQ:ARQL | ArQule Inc |
| 10/30/2019 | 10:57AM | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:ARQL | ArQule Inc |
| 10/30/2019 | 7:30AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ARQL | ArQule Inc |
| 10/30/2019 | 7:00AM | Business Wire | ArQule Reports Third Quarter 2019 Financial Results | NASDAQ:ARQL | ArQule Inc |
| 10/29/2019 | 4:01PM | Business Wire | ArQule Presents Recent Data on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets & Cancer Ther... | NASDAQ:ARQL | ArQule Inc |
| 10/21/2019 | 7:00AM | Business Wire | ArQule Announces Preclinical Data Demonstrating Potential of Miransertib (ARQ 092) to Treat PIK3CA-Driven Vascular Malformati... | NASDAQ:ARQL | ArQule Inc |